Switch to injectable cabotegravir-rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial.

Bwakura-Dangarembizi M, Chappell E, Kityo C, Anena DL, Kiilu C, Archary M, Jafta L, Mujuru HA, Nakabuye S, Akabwai GP, Siika A, Mngqibisa R, Mugerwa H, Walker S, Seeley J, Burger D, Omar A, South A, Nguyen H, Giaquinto C, Spittle B, Bamford A, Kekitiinwa AR, Ford D, Pett S, LATA trial team

Open source

DOI: 10.1016/s0140-6736(26)01537-0
Published: 2026 Sep 17
Container: Lancet (London, England)
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-26-01537-0,
  title = {Switch to injectable cabotegravir-rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial.},
  author = {Bwakura-Dangarembizi M and Chappell E and Kityo C and Anena DL and Kiilu C and Archary M and Jafta L and Mujuru HA and Nakabuye S and Akabwai GP and Siika A and Mngqibisa R and Mugerwa H and Walker S and Seeley J and Burger D and Omar A and South A and Nguyen H and Giaquinto C and Spittle B and Bamford A and Kekitiinwa AR and Ford D and Pett S and LATA trial team},
  year = {2026},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(26)01537-0},
  url = {https://doi.org/10.1016/s0140-6736(26)01537-0}
}

RIS

TY  - JOUR
TI  - Switch to injectable cabotegravir-rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial.
AU  - Bwakura-Dangarembizi M
AU  - Chappell E
AU  - Kityo C
AU  - Anena DL
AU  - Kiilu C
AU  - Archary M
AU  - Jafta L
AU  - Mujuru HA
AU  - Nakabuye S
AU  - Akabwai GP
AU  - Siika A
AU  - Mngqibisa R
AU  - Mugerwa H
AU  - Walker S
AU  - Seeley J
AU  - Burger D
AU  - Omar A
AU  - South A
AU  - Nguyen H
AU  - Giaquinto C
AU  - Spittle B
AU  - Bamford A
AU  - Kekitiinwa AR
AU  - Ford D
AU  - Pett S
AU  - LATA trial team
PY  - 2026
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(26)01537-0
UR  - https://doi.org/10.1016/s0140-6736(26)01537-0
ER  -

APA

M, B., E, C., C, K., DL, A., C, K., M, A., L, J., HA, M., S, N., GP, A., A, S., R, M., H, M., S, W., J, S., D, B., A, O., A, S., H, N., C, G., B, S., A, B., AR, K., D, F., S, P., & team, L. T. (2026). Switch to injectable cabotegravir-rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(26)01537-0

Source records

pubmed · retrieved 2026-09-25T14:49:57.886Z
europe-pmc · retrieved 2026-09-25T14:49:57.897Z